Final decision on call option over Natraceutical

Regarding the call option of Brazilian company Bio Group Brazil over the stake that Natra holds in Natraceutical

Regarding the agreement of understanding between Natraceutical and the Brazilian company Bio Group Brazil for the joint-development of Forté Pharma in Brazil as well as a potential acquisition of a majority stake in Natraceutical resulting from a call option with Natraceutical’s parent company Natra, after the first four-months period for the execution of the call option Bio Group Brazil has informed Natra about its decision to reject the call option contract. This decision does not affect however the joint-business project in Brazil, on which both companies are progressing.

Download original text (PDF)